Loading
M2Gen, a wholly-owned for-profit subsidiary of the Tampa-based Moffitt Cancer Center, has named Cathy Kerzner its new chief commercial officer.
Kerzner joins the company from Wyeth Pharmaceuticals, where she served as senior vice president of commercial portfolio management.
“Cathy brings a great mix of deep commercial skills and broad corporate experience, having held leadership roles in both startups and Big Pharma,” said James Utterback, CEO at M2Gen, in a release. “Her international experience will certainly be tapped as we expand the M2Gen footprint outside of our focus in North America.”
M2Gen is working to develop cancer treatments that utilize a patient's genetic information, a field known more broadly as personalized medicine.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
